For Immediate Release


Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program

Tokyo, Japan (July 20, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will open applications for participating in its sponsored, investigator-initiated studies program for researchers at Japanese universities or government research institutes.


1. Overview & Purpose

Daiichi Sankyo has long supported researchers engaged in investigator-initiated clinical studies using Daiichi Sankyo pharmaceutical products, and is opening applications with the objective of seeking ideas from a broad range of perspectives while further enhancing compliance and transparency in its business activities.


2. Project Overview

(1) Applicable research

Researchers engaged in investigator-initiated clinical studies relating to Daiichi Sankyo pharmaceutical products, within the scope of the Ethical Guidelines for Medical and Health Research Involving Human Subjects; set by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, and the scope of the drug package insert of approved pharmaceuticals (indication, dosage and administration), are invited to apply.


(2) Desired research themes

       1. Field:         Circulatory system

       2. Diseases      Atrial fibrillation (oral anticoagulants)

                            Venous thromboembolism (oral anticoagulants)


Applications relating to research in other fields involving Daiichi Sankyo pharmaceutical products will also be considered. However, studies in the above fields will be given priority.


(3) Eligibility

Researchers at universities and government research institutes in Japan who are capable of leading clinical trials as the principal investigator and conducting research appropriately in accordance to a predetermined plan as well as ensuring patients’ safety.


(4) Schedule

Applications open on July 31, 2017, and remain open all year


(5) How to apply

Apply from the Sponsored Investigator-Initiated Studies Program page on Daiichi Sankyo’s corporate website

For further details, please see the Sponsored Investigator-Initiated Studies Program on the Daiichi Sankyo website: